Analysts at William Blair lifted their Q2 2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. William Blair analyst L.

A team of experts from The Johns Hopkins Applied Physics Laboratory, in Laurel, and The Johns Hopkins University’s Whiting School of Engineering is leveraging artificial intelligence to enable faster ...

Nobody likes sweaty feet. Not on ourselves, not on our partners, not on anyone close to us, in physical distance and in ...

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

Well attended poetry sessions, heated environmental discussions, and talks on the changing dyamics of tribal people were ...

Less than two weeks after having its funding temporarily cut by the state, the Fairhope Public Library is getting recognized ...

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

The National Population Commission (NPC) has called for increased collaboration among stakeholders to tackle Nigeria’s ...

The Alabama Public Library Service (APLS) voted to pause $40,000 in funding to the Fairhope Public Library after the ...